Transesophageal Versus Intracardiac Echocardiogram in Patients at High-Risk for Thromboembolic Events Undergoing Atrial Fibrillation Ablation

2021 ◽  
Author(s):  
David Felipe Briceno ◽  
Jorge Romero ◽  
Seth B. Newman ◽  
Isabella Alviz ◽  
Akhil Parashar ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
High Risk ◽  
Atrial Fibrillation Ablation ◽  
Thromboembolic Events ◽  
Intracardiac Echocardiogram

Adherence, knowledge, and perception about oral anticoagulants in patients with atrial fibrillation at high risk for thromboembolic events after radiofrequency ablation

2018 ◽  
Vol 74 (11) ◽  
pp. 2577-2587 ◽  
Author(s):  
Lily Smet ◽  
Ward A. Heggermont ◽  
Eva Goossens ◽  
Kristof Eeckloo ◽  
Robert Vander Stichele ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Radiofrequency Ablation ◽  
High Risk ◽  
Oral Anticoagulants ◽  
Thromboembolic Events

scholarly journals 1052-222 Thromboembolic events in patients undergoing atrial fibrillation ablation-incidence, timing, and predictors

2004 ◽  
Vol 43 (5) ◽  
pp. A115
Author(s):  
Mark E Vanderhoff ◽  
Erica S Zado ◽  
Edward P Gerstenfeld ◽  
Sanjay Dixit ◽  
Hemal Nayak ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Atrial Fibrillation Ablation ◽  
Thromboembolic Events

Mitral regurgitation associated with reduced thromboembolic events in high-risk patients with nonrheumatic atrial fibrillation

1993 ◽  
Vol 72 (11) ◽  
pp. 840-843 ◽  
Author(s):  
Joseph L. Blackshear ◽  
◽  
Lesly A. Pearce ◽  
Richard W. Asinger ◽  
Howard C. Dittrich ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
High Risk ◽  
Mitral Regurgitation ◽  
Thromboembolic Events ◽  
High Risk Patients ◽  
Risk Patients

scholarly journals Anticoagulant therapy in a patient with a history of cerebral hemorrhage

ABOUTOPEN ◽  
2018 ◽  
Vol 4 (1) ◽  
pp. 191-195
Author(s):  
Mario Crisci
Keyword(s):  
Atrial Fibrillation ◽  
Clinical Practice ◽  
High Risk ◽  
Anticoagulant Therapy ◽  
Safety Profile ◽  
Hemorrhagic Stroke ◽  
Thromboembolic Events ◽  
Final Choice ◽  
Off Label ◽  
History Of

Several guidelines recommend the preferential use of NOAC compared to warfarin in patients with atrial fibrillation, based on evidence to support a efficacy similar to warfarin, but with a lower incidence of intracranial hemorrhage. The case described is a typical example of non-optimal use of NOACs in clinical practice: although the final choice of dabigatran 110 mg bid is in line with the recommendations of the guidelines and with the literature, the previous choice of administering enoxaparin is inadequate due to the presence of atrial fibrillation which makes the use of the drug off-label due to the lack of clinical data in this type of patient. Nevertheless, use of enoxaparin waiting to optimize anticoagulant therapy is very common in clinical practice. Non-inferiority in reagards to thromboembolic events and a superior safety profile in comparison to warfarin in the RE-LY study, make dabigatran 110 mg bid a suitable choice in clinical practice for patients at high risk of both thrombotic and hemorrhagic stroke (Cardiology).

scholarly journals THE ENDOVASCULAR PREVENTION OF THROMBOEMBOLISM IN ATRIAL FIBRILLATION

2018 ◽  
pp. 104-114
Author(s):  
Rami N. Al-Ayyubi ◽  
Evgeny V. Merkulov ◽  
Andrey S. Tereschenko ◽  
Dmitry V. Pevzner ◽  
Natalia S. Zhukova ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
High Risk ◽  
Anticoagulant Therapy ◽  
Oral Anticoagulant ◽  
Oral Anticoagulant Therapy ◽  
Drug Prevention ◽  
Thromboembolic Events ◽  
Risk Of Bleeding ◽  
Prevention Of Thromboembolic Events

The article dwells upon the various strategies for prevention of thromboembolic events in patients with atrial fibrillation. The main focus is put on the endovascular strategies for prevention of tromboembolism. In recent years, the endovascular strategies for the prevention of thromboembolic events in patients with atrial fibrillation, who have contraindications to oral anticoagulant therapy, are increasingly gaining popularity and find evidence of its safety for the prevention of thromboembolism. The patients with AF with a high risk of bleeding is the most interesting category for studying. The large studies confirm the effectiveness of non-drug prevention of thromboembolic events as compared to the anticoagulant therapy in these patients.

Sign in / Sign up

Export Citation Format

Share Document